<DOC>
	<DOCNO>NCT01555008</DOCNO>
	<brief_summary>This Phase 1 study intend assess pharmacodynamics ( PD ) , pharmacokinetics ( PK ) , safety tolerability LX4211 follow daily oral administration subject type 2 diabetes mellitus ( T2DM ) moderate severe renal impairment .</brief_summary>
	<brief_title>Study Evaluate Pharmacodynamic Pharmacokinetic Effects LX4211 Subjects With Type 2 Diabetes Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Adults ≥18 ≤80 year age History T2DM least 6 month prior screen Moderate severe renal impairment actively dialysis Willing able perform selfmonitoring blood glucose Willing able provide write informed consent History type 1 diabetes mellitus , diabetic ketoacidosis ( within previous 6 month ) , diabetes result pancreatic disorder secondary diabetes ( acromegaly and/or Cushing 's disease ) Subjects receive renal allograft Subjects expect require dialysis undergo kidney transplantation within 3 month study dose Presence active hepatic disease clinically significant abnormal liver function test Screening plan study Day 1 Subjects history heart attack , severe/unstable angina , coronary revascularization procedure within 6 month prior study Day 2 History clinically significant cardiac arrhythmia within 1 year prior study Day 2 Subjects congestive heart failure Subjects uncontrolled Stage III hypertension History 2 emergency room visit , doctor ' visit , hospitalization due hypoglycemia within 6 month prior plan study Day 2 History alcohol illicit drug abuse within 1 year prior Screening History human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Major surgery within 6 month prior plan study Day 2 History malignancy within last 5 year Triglycerides &gt; 1000 mg/dL Screening plan study Day 1 History serious adverse reaction hypersensitivity SGLT inhibitor Use corticosteroid within 2 week prior study Day 1 Use investigational drug within 30 day prior study Day 1 , investigational protein antibody within 60 day Day 1 Positive urine pregnancy test Screening Positive urine screen illicit drug abuse Screening Prior exposure LX4211</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>